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Short Communication 
Activation of Methotrexate Prodrugs by Enzyme/Monoclonal Antibody 
Conjugates 
K. S. Vitols, E. Haenseler1 ', Y. Montejano, T. Baer2) and F. M. Huennekens 
Division of Biochemistry, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 
La Jolla, California 92037, U. S. A. 
(Received M a r c h 1992) 
One of the major goals in cancer chemotherapy is the 
development of procedures for the selective delivery 
of drugs to tumor cells. This strategy, when perfected, 
will allow drugs to be used at the high concentrations 
necessary for virtually complete (i. e., > 99%) eradi-
cation of the tumor cells without concomitant destruc-
tion of normal cells. Monoclonal antibodies targeted 
to tumor antigens offer considerable promise for ef-
fecting the desired selectivity. To date, however, only 
limited success has been achieved in clinical trials with 
monoclonals as vehicles for carrying drugs. Two lim-
itations are evident in the use of drug-monoclonal 
conjugates: (a) Relatively few drug molecules can be 
linked to each monoclonal without impairing binding 
activity; and (b) A mechanism is needed to release 
covalently-bound drug from the antibody. In an effort 
to overcome these problems, attention has focused 
recently on the attachment of enzymes rather than 
drugs to monoclonals, thereby taking advantage of 
the catalytic power of the enzyme to generate large 
amounts of the active drugs f rom inert prodrugs at 
the tumor site [reviewed by Senter (1)]. 
Methotrexate (MTX), employed extensively in cancer 
chemotherapy, is well-suited to the prodrug/enzyme-
monoclonal conjugate strategy. α-Peptides of the drug 
(i.e., derivatives in which the a - C O O H has been 
linked to an amino acid) are relatively non-toxic, but 
these derivatives can be hydrolyzed by carboxypep-
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tidases to yield the active parent drug. Alanine, phen-
ylalanine, aspartate and arginine derivatives of MTX 
(Fig. 1) have been synthesized in good yield by con-
ventional pathways (2, 3). It Should be noted, how-
ever, that direct coupling of the amino acid to M T X 
results in considerable racemization of the L-gluta-
mate moiety in the drug which, in turn, limits the 
carboxypeptidase-mediated cleavage of the MTX-
amino acid linkage. This can be avoided by coupling 
the Glu-amino acid dipeptide to 4-amino-4-deoxy-10-
methylpteroic acid. Hydrolysis of the MTX oc-peptides 
by various carboxypeptidases, and particularly MTX-
Ala by carboxypeptidase-A (CP-Α), has been exam-
ined in detail (2). These reactions, although slow 
relative to the rates with standard substrates for the 
enzymes (e.g.. hippurylphenylalanine for CP-Α), are 
still sufficient to generate toxic quantities of the drug 
( 2 ) . 
Regional selectivity of the MTX-Ala/CP-A combi-
nation was demonstrated in a model system in which 
immobilized CP-Α was embedded in a semi-solid me-
dium containing the prodrug and LI210 cells (4). The 
crucial question, however, was whether cytotoxic 
combinations of MTX could be produced by the 
amount of CP-Α that could be attached to target cells 
via a monoclonal antibody. Accordingly, CP-Α deri-
vatized with succinimidyl 4-(N-maleimidome-
thyl)cyclohexane-l-carboxylate and a monoclonal an-
tibody (KS 1/4, directed toward a surface antigen on 
carcinoma cells) derivatized with N-succinimidyl 3-
(2-pyridyldithio)propionate were reacted to produce 
a thioether-linked, enzyme-antibody conjugate prep-
aration (5). The latter, purified by sequential H P L C 
size-exclusion and D E A E chromatography, contained 
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Figure 1. Structures of Methotrexate α-peptides. 
Table 1. Cytotoxicity of Methotrexate α-Phenylalanine (MTX-
Phe) for U C L A - P 3 Cells Treated with Carboxypept idase-A 
(CP-A)/Monoclonal Ant ibody KS1/4 Conjugate 
Drug Enzyme- % 
or Prodrug Monoclonal Inhibition 
Conjugate 
M T X 100 
MTX-Phe C P - A / K S l / 4 94 
MTX-Phe — 23 
— C P - A / K S l / 4 3 
In vitro cytotoxicity against UCLA-P3 human lung adenocar-
cinoma cells (104 cells/well) was measured in 96-well plates as 
described previously (5). In samples treated with enzyme-anti-
body conjugate, excess of the latter was removed by extensive 
washing. Growth was stopped af ter 72 h. Inhibit ion is expressed 
relative to tha t observed with M T X (designated as 100%). 
Concentrat ions of M T X and MTX-Phe , 1 χ ΙΟ"6 M. 
NH, 
approximately equal amounts of 1 : 1 and 2 : 1 (en-
zyme : antibody) conjugates. Binding activity of the 
conjugate (1.8 χ IO5 molecules/cell) was similar to 
that of unreacted antibody. 
In vitro cytotoxicity studies using UCLA-P3 human 
lung adenocarcinoma cells (2 χ IO4 cells/well) in 96-
well plates demonstrated that the amount of free ΟΡ-
Α required to produce ID50 values for MTX prodrugs 
equal to that of MTX (ca. 5 χ 10 8 m) was 10 mU/ 
well for MTX-Ala, and 1 mU for MTX-Phe. How-
ever, calculations based upon the number of antigen 
binding sites per cell and the CP-Α activity of the 
KS1/4 conjugate indicated that only about 0.03 mU 
of enzyme would be present on cells saturated with 
conjugate. It was a pleasant surprise to find that, 
when the lung tumor cells were treated with the con-
jugate, and excess unbound conjugate was removed 
by extensive washing prior to addition of the prodrug, 
the ID50 for MTX-Ala improved from 8.9 χ 10 6 M 
(no CP-A or conjugate) to 1.5 χ 10~6 m for cells 
containing bound conjugate. With MTX-Phe as a 
prodrug, the results were even better: ID50 in the 
presence of conjugate approached that of MTX (5.2 
χ ΙΟ - 8 m). The conjugate-mediated toxicity of MTX-
Phe is illustrated by an experiment (Table 1 ) in which 
identical concentrations of the drug and prodrug are 
compared for their ability to inhibit cell replication. 
Increased potentiation of prodrug cytotoxicity by an-
tibody-bound CP-Α over that afforded by free enzyme 
is attributed to enhanced effectiveness of MTX gen-
erated adjacent to folate transporters at the cell sur-
face. These results clearly demonstrate the in vitro 
chemotherapeutic potential of carboxypeptidase-
monoclonal antibody conjugates used in conjunction 
with MTX peptide prodrugs. 
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